Background: Musculoskeletal pain is a common condition, and patients who have it may transition to chronic opioid use. However, the risk and risk factors for chronic opioid use among patients with new musculoskeletal pain are not fully understood.
Objective: To characterize the risk and risk factors for chronic opioid use among opioid-naive patients with newly diagnosed musculoskeletal pain in the knee, neck, low back, or shoulder.
Methods and Findings:
The IBM MarketScan database provides data on health care use by patients receiving private insurance through a participating employer or government organization. Compared with the general U.S. population, the MarketScan population is slightly more likely to be female, more likely to come from the southern United States, and less likely to come from the western United States (1). Using these data for 1 January 2007 to 31 December 2015, we identified 518 195 adults who were privately insured, cancer-free, opioid-naive (no filled opioid prescriptions in the year before diagnosis), and aged 18 to 64 years; were diagnosed with non-trauma-related musculoskeletal pain between 1 January 2008 and 31 December 2014; and remained continuously enrolled for the year before and the year after the initial diagnosis. Because the severity of musculoskeletal pain can vary, we restricted our analysis to patients with pain severe enough to result in a second outpatient or emergency department visit for musculoskeletal pain within 30 days of the initial diagnosis (2). We excluded 6036 patients with missing opioid data and 100 138 with conditions that could be mistaken for musculoskeletal low back pain (nephrolithiasis, urinary tract infection, osteomyelitis, cholecystitis, osteoporosis, cauda equina syndrome, and osseous defect), resulting in a final sample of 412 021 patients.
We defined chronic opioid use as filling 10 or more prescriptions or having at least 120 days' supply of the following opioids between 91 and 365 days after the initial diagnosis: hydrocodone, hydromorphone, methadone, morphine, oxymorphone, and oxycodone. We then estimated the annual risk for chronic opioid use and used multivariable logistic regression to characterize its association with the following risk factors: pain region or multiple sites (pain in >1 region); age; sex; severity of medical comorbid conditions using the van Walraven score (3); opioid use in the 90 days after diagnosis; and use of benzodiazepines, antidepressants, antipsychotics, gabapentin, or pregabalin in the year before diagnosis. Our choice of risk factors and definition of chronic opioid use were based on previous work (4).
Our sample had 209 391 men (51%), and the average age was 45 years (SD, 12). For the entire sample period, annual unadjusted risks for chronic opioid use were 0.43% for neck pain, 0.3% for shoulder, 0.3% for knee, 1.4% for low back, and 1.5% for multiple sites. Knee pain, low back pain, and multiple-site pain decreased during the period (P < 0.001) ( Figure) . The overall risk for chronic opioid use across our sample was 0.31% (95% CI, 0.29% to 0.33%). We identified several risk factors, most notably anatomical location (for example, low back and multiple sites) and opioid use within 90 days of diagnosis (Table) .
Discussion: Risk for chronic opioid use ranged from 0.3% for knee pain to 1.5% for multiple-site pain and decreased for some anatomical regions between 2008 and 2014, suggesting that recent efforts to reduce opioid use have had some success. However, other studies have found increases in opioid use (5), albeit using alternative populations, time periods, and outcomes (such as overdose deaths). Study limitations include the following: 1) The sample was restricted to privately insured patients, thereby excluding other policy-relevant populations (such as Medicaid); 2) "opioid-naive" patients may have used opioids in ways not captured in the data (for example, illegal use or use >1 year before diagnosis); 3) although we assumed that a second visit for pain indicates severity, it could also indicate anxiety or dissatisfaction; and 4) patients may have had musculoskeletal pain for a long period before diagnosis. In sum, our data suggest that risk for chronic opioid use among patients with musculoskeletal pain has decreased and point to some measures (such as avoiding opioid use soon after diagnosis) to further reduce this risk, particularly among those with the risk factors identified here (for example, low back and multiple-site pain). Patients with these risk factors should be closely followed and may benefit from involvement of a nonpharmacologic provider, such as a physical therapist or chiropractor. 
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